×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LSTA – lisata therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LSTA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
06:43 am
lsta
Lisata Therapeutics (NASDAQ:LSTA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Lisata Therapeutics (NASDAQ:LSTA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/9
12:53 am
lsta
Lisata (LSTA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Lisata (LSTA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/7
12:20 am
lsta
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... [Yahoo! Finance]
Medium
Report
Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... [Yahoo! Finance]
11/6
04:05 pm
lsta
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
11/6
08:00 am
lsta
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
Low
Report
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
11/4
04:00 pm
lsta
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
High
Report
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
10/30
08:00 am
lsta
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
Low
Report
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
10/14
07:58 am
lsta
Lisata Therapeutics (NASDAQ:LSTA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Lisata Therapeutics (NASDAQ:LSTA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:05 pm
lsta
lisata therapeutics, inc.
BEAT
Report
-6.4%
lisata therapeutics, inc.
5/8/2025
04:05 pm
lsta
lisata therapeutics, inc.
MISS
Report
-11.6%
lisata therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/6
04:19 pm
lsta
Form 10-Q LISATA THERAPEUTICS, For: Sep 30
High
Report
Form 10-Q LISATA THERAPEUTICS, For: Sep 30
11/6
04:13 pm
lsta
Form 8-K LISATA THERAPEUTICS, For: Nov 06
High
Report
Form 8-K LISATA THERAPEUTICS, For: Nov 06
10/14
04:03 pm
lsta
Form 8-K LISATA THERAPEUTICS, For: Oct 14
Low
Report
Form 8-K LISATA THERAPEUTICS, For: Oct 14
10/8
03:13 pm
lsta
Form 8-K LISATA THERAPEUTICS, For: Oct 08
Low
Report
Form 8-K LISATA THERAPEUTICS, For: Oct 08
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: